Excess Toxicity Associated with Docetaxel and Irinotecan in Patients with Metastatic, Gemcitabine-Refractory Pancreatic Cancer: Results of a Phase II Study

By Ko Andrew   Dito Elizabeth   Schillinger Brian   Venook Alan   Bergsland Emily   Tempero Margaret  

Cancer Investigation, Vol. 26, Iss. 1, 2007-12 ,pp. : 47-52

Informa Healthcare

Access to resources Recommend Favorite

Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer

By Takahara Naminatsu   Nakai Yousuke   Isayama Hiroyuki   Sasaki Takashi   Satoh Yumiko   Takai Daiya   Hamada Tsuyoshi   Uchino Rie   Mizuno Suguru   Miyabayashi Koji   Mohri Dai   Kawakubo Kazumichi   Kogure Hirofumi   Yamamoto Natsuyo   Sasahira Naoki   Hirano Kenji   Ijichi Hideaki   Tada Minoru   Yatomi Yutaka   Koike Kazuhiko  

Cancer Chemotherapy and Pharmacology, Vol. 71, Iss. 1, 2013-01 ,pp. : 85-92

Springer Publishing Company

Access to resources Recommend Favorite

MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer

By Paule Bernard  

Medical Oncology, Vol. 27, Iss. 4, 2010-12 ,pp. : 1066-1072

Humana Press, Inc

Access to resources Recommend Favorite

Future perspectives in the treatment of pancreatic cancer

By Heinemann V.  

memo - Magazine of European Medical Oncology, Vol. 1, Iss. 1, 2008-03 ,pp. : 27-30

Springer Publishing Company

Access to resources Recommend Favorite

Combination Therapy for the Treatment of Pancreatic Cancer

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 11, Iss. 5, 2011-06 ,pp. : 418-426

Bentham Science Publishers

Access to resources Recommend Favorite